STOCK TITAN

Oliver Wyman Completes Acquisition of Huron’s Life Sciences Strategy Consulting Practice

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Rhea-AI Summary

Oliver Wyman, a consulting firm within Marsh McLennan (NYSE: MMC), has acquired Huron's life sciences strategy consulting practice. The deal enhances Oliver Wyman's capabilities in healthcare, allowing for comprehensive solutions to complex industry challenges. With this acquisition, Oliver Wyman adds 80 skilled professionals, including 12 partners, expanding its talent pool and client relationships within the pharmaceutical and biotechnology sectors. This strategic move aims to strengthen Oliver Wyman's leadership in life sciences consulting and broaden its service offerings.

Positive
  • Acquisition adds 80 professionals, including 12 partners, enhancing talent pool.
  • Strengthens leadership in life sciences strategy consulting.
  • Expands service offerings in commercial strategy, marketing, and R&D.
Negative
  • None.

NEW YORK--(BUSINESS WIRE)-- Oliver Wyman, a global management consulting firm and a business of Marsh McLennan (NYSE: MMC), today completed the acquisition of Huron’s life sciences strategy consulting practice. Terms of the acquisition were not disclosed.

“Through this combination, we will continue our relentless pursuit of a better way in healthcare, partnering with pharmaceutical, biotechnology, and medical device companies. Our new colleagues bring the expertise needed to help life sciences companies tackle their most pressing strategic questions, including increasingly complex commercialization and access-related issues,” commented Sam Glick, Partner and Global Leader of Health and Life Sciences at Oliver Wyman.

“Combining the deep industry expertise of the Huron Life Sciences team with Oliver Wyman’s global scale and capabilities, will help us holistically address the challenges of the life sciences sector,” said John Westwood, Partner and Global Life Sciences Business Leader at Oliver Wyman and former Global Life Sciences Practice Leader at Huron. “Now as part of Oliver Wyman, we look forward to working side-by-side with our clients to help shape healthcare’s future.”

The acquisition advances Oliver Wyman’s leadership in life sciences strategy consulting, helping the firm deliver critical commercial strategy, marketing, pricing, market access, and R&D advice to a broader set of clients.

The acquisition also grows Oliver Wyman’s deep bench of talent, adding 80 professionals, including 12 partners, to its Health and Life Sciences practice. These senior professionals have longstanding relationships with many of the world’s top pharmaceutical, biotechnology, diagnostics, and medical device companies.

About Oliver Wyman
Oliver Wyman is a global leader in management consulting. With offices in 60 cities across 29 countries, Oliver Wyman combines deep industry knowledge with specialized expertise in strategy, operations, risk management, and organization transformation. The firm has more than 5,000 professionals around the world who work with clients to optimize their business, improve their operations and risk profile, and accelerate their organizational performance to seize the most attractive opportunities. Oliver Wyman is a business of Marsh McLennan (NYSE: MMC). For more information, visit www.oliverwyman.com. Follow Oliver Wyman on Twitter @OliverWyman.

Francine Minadeo

Oliver Wyman

+1 917-573-8826

Francine.minadeo@oliverwyman.com

Source: Oliver Wyman

FAQ

What was the purpose of Oliver Wyman's acquisition of Huron's life sciences practice?

The acquisition aims to enhance Oliver Wyman's capabilities in healthcare consulting and to address complex challenges faced by life sciences companies.

How many professionals did Oliver Wyman gain from the acquisition?

Oliver Wyman gained 80 professionals, including 12 partners, from Huron's life sciences strategy consulting practice.

What impact does the acquisition have on Oliver Wyman's services?

The acquisition strengthens Oliver Wyman's service offerings in areas such as commercial strategy, pricing, marketing, and R&D advice.

When was the acquisition of Huron's life sciences practice completed?

The acquisition was completed recently; however, the exact date was not disclosed in the press release.

Marsh & McLennan Companies, Inc.

NYSE:MMC

MMC Rankings

MMC Latest News

MMC Stock Data

109.96B
492.72M
0.09%
90.97%
0.91%
Insurance Brokers
Insurance Agents, Brokers & Service
Link
United States of America
NEW YORK